Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients by Pejša, Vlatko et al.
40
www.cmj.hr
Received: August 10, 2016
Accepted: February 13, 2017
Correspondence to: 
Vlatko Pejša 
Department of Hematology 
University Hospital Dubrava 
Av. Gojka Šuška 6 
10000 Zagreb, Croatia 
vpejsa@kbd.hr
Vlatko Pejša1,2, Željko Prka1, 
Marko Lucijanić1, Zdravko 
Mitrović1,2, Mario Piršić1, 
Ozren Jakšić1,2, Radmila 
Ajduković1, Rajko Kušec1,2
1Department of Hematology, 
University Hospital Dubrava, 
Zagreb, Croatia
2School of Medicine, University of 
Zagreb, Zagreb, Croatia
Aim To assess the benefit of rituximab with dose-adjusted 
etoposide, prednisone, vincristine, cyclophosphamide, and 
doxorubicin (R-DA-EPOCH) regimen as a first-line treat-
ment for patients with diffuse large B-cell lymphoma (DL-
BCL) presenting with unfavorable or aggressive features, 
and autologous stem cell transplantation (ASCT) as a part 
of the first-line treatment for selected DLBCL patients with 
additional aggressive features.
Methods We retrospectively analyzed 75 newly diagnosed 
DLBCL patients with Ki-67+≥80% or International Prognos-
tic Index ≥2 who were treated with R-DA-EPOCH between 
2005 and 2015. Of 24 DLBCL patients with additional ag-
gressive features (Ki-67+≥90% or age-adjusted IPI≥2) who 
were planned to receive consolidation with ASCT, 17 pa-
tients underwent the procedure. We determined the over-
all response rate (ORR), complete remission (CR), partial re-
mission (PR), 5-year overall survival (OS), and progression 
free survival (PFS) in all DLBCL patients and specifically 
those planned to receive ASCT.
Results All 75 patients included in the analysis started one 
or more cycles of therapy. The ORR, CR, and PR rates were 
80%, 55%, and 25%, respectively. The response was non-
evaluable in 10 of 75 patients due to treatment discontinu-
ation. The OS and PFS rates for all 75 patients were 70% and 
61%, respectively, and 80% and 79%, respectively, for 24 
planned-to-receive-ASCT patients. Age (≤65 vs >65 years) 
had no prognostic impact on OS and PFS (P = 0.994 and 
P = 0.827, respectively).
Conclusion Our retrospective analysis of one of the larg-
est DLBCL patient cohorts outside the US National Cancer 
Institute showed that R-DA-EPOCH is a very effective ther-
apeutic option as a first-line treatment of DLBCL patients 
with unfavorable prognostic features irrespective of their 
age. ASCT provided additional benefit for DLBCL patients 
with additional aggressive features.
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Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon aggressive type of B-cell lymphoma (1). It has multiple 
morphologic variants and heterogeneous molecular back-
ground (2). DLBCL treatment failure depends on a variety 
of factors, including tumor biology, tumor volume, phar-
macokinetics, and pharmacogenomics (3-5). Various prog-
nostic scores were developed to differentiate patients with 
unfavorable prognosis. The International Prognostic Index 
(IPI) (6,7) and its derivative, the revised IPI (R-IPI) (8), are the 
primary clinical tools for outcome prediction in the era of 
R-CHOP, an immunochemotherapy regimen combining 
rituximab, cyclophosphamide, doxorubicin hydrochloride, 
vincristine sulfate, and prednisone. The age-adjusted IPI 
(aaIPI) has also been extensively used in the studies adopt-
ing intensive treatment approaches, such as high-dose 
therapy and stem cell transplantation (9,10). Even though 
R-CHOP has been a gold standard in DLBCL therapy, there 
are raising concerns about the efficacy of this regimen, es-
pecially in younger patients with poor prognostic factors 
(11). Several R-CHOP modifications were explored with the 
intention to improve upfront treatment but did not pro-
vide any significantly better results due to greater toxicity 
(12-15). However, some aggressive alternative regimens 
improved the outcomes in selected groups of patients, but 
their applicability has been restricted to younger patients 
due to high acute and long-term toxicities (16,17).
A dose-adjusted regimen combining etoposide, pred-
nisone, vincristine, cyclophosphamide, and doxorubicin 
(DA-EPOCH) was developed as a continuous infusion regi-
men relying on a concept that tumor cells display relatively 
less resistance to a prolonged drug exposure in compari-
son with brief higher concentration exposure (18). Dynam-
ic dose adjustments according to patient’s bone marrow 
status (observed as the absolute neutrophil and platelet 
counts) allow for the use of the highest acceptable doses 
of drugs, while avoiding additional toxicity and improving 
the results (19). Thus, this treatment approach is suitable 
for older patients. Rituximab with DA-EPOCH (R-DA-EP-
OCH) demonstrated efficacy in treatment of patients with 
DLBCL (20-22). Superior progression-free survival has been 
observed in a subset of DLBCL patients harboring c-myc 
and bcl-2 rearrangements, termed “double hit” lympho-
mas, treated with R-DA-EPOCH regimen in comparison to 
R-CHOP regimen-treated patients (23,24). The role of autol-
ogous stem cell transplantation (ASCT) as part of a first-line 
therapy in DLBCL is still unresolved. Although it is generally 
not recommended because it has no impact on the overall 
survival (25), it might have a role in first-line treatment of 
patients with poor prognostic features (11,26,27).
The aim of our study was to determine the benefit of R-DA-
EPOCH regimen as a first-line treatment for DLBCL patients 
presenting with unfavorable or aggressive features and 
ASCT as part of first-line treatment in a subgroup of DLBCL 
patients with additional aggressive features.
PATIENTS AND METHODS
This retrospective cohort study was performed at the De-
partment of Hematology, University Hospital Dubrava in 
Zagreb, Croatia, from May 2005 to December 2015.
Patients
A total of 75 patients with newly diagnosed DLBCL and 
unfavorable prognostic features, defined as a very high 
proliferative index Ki-67+≥80% and/or IPI≥2, were treated 
with R-DA-EPOCH regimen during the study period (Table 
1). A subset of 24 DLBCL patients who initially presented 
TAbLE 1. Characteristics, treatment, and clinical outcomes in 
all patients with diffuse large b cell lymphoma (DLbCL) and a 
subgroup of DLbCL patients planned to receive autologous 
stem cell transplantation (ASCT)*
No. of DLbCL patients
Characteristics
total 
(n = 75)
planned to 
receive ASCT 
(n = 24)
Sex (male/female) 42/33 12/12
Age (years; median, IQR) 61 (47-71) 50 (41-57)
Ann Arbor III & IV 61 21
High LDH 57 21
ECOG≥2 26 11
>1 extranodal presentation 37 12
Bulky disease 28 11
Ki-67 ≥ 80% 31  8
Ki-67 ≥ 90% 18  7
B symptoms 37 15
IPI≥2 64 20
Age-adjusted IPI≥2 - 18
R-IPI poor risk 45 12
R-DA-EPOCH cycles (median, IQR)  6 (6-8)  7 (6-7)
ASCT transplantation 17 17
CD34+ cells mobilized with EPOCH  - 18/21†
Irradiation  7  2
*Abbreviations: IQR – interquartile range; LDH – lactate dehydro-
genase; ECOG – Eastern Cooperative Oncology Group; b symptoms 
– fever, weight loss, and night sweats; IPI –International Prognostic 
Index; R-IPI – revised IPI; R-DA-EPOCH – rituximab plus dose-adjusted 
regimen combining etoposide, prednisone, vincristine, cyclophosph-
amide, and doxorubicin.
†Three patients planned to receive ASCT died prior to stem cell 
mobilization.
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with additional aggressive features (Ki-67+≥90% and/
or aaIPI≥2) and had no transplant-limiting comorbidities 
were planned to undergo ASCT as part of first-line therapy. 
Seven patients received concomitant radiation therapy. All 
patients provided written informed consent for therapy.
Chemotherapeutic regimen
Original DA-EPOCH regimen (20) consists of continuous in-
travenous infusion of etoposide 50 mg/m2/d on days 1 to 
4, oral prednisone 60 mg/m2/d on days 1 to 5, continuous 
infusion of vincristine (Oncovine) 0.4 mg/m2/d on days 1 
to 4, cyclophosphamide 750 mg/m2/d administered intra-
venously over 15 minutes on day 5, continuous infusion of 
doxorubicin (Hydroxydaunorubicin) 10 mg/m2/d on days 
1 to 4, and filgrastim 5 μg/kg administered subcutane-
ously from day 6 until the absolute neutrophil count (ANC) 
reaches 10 × 109/L. The regimen is repeated every three 
weeks. DA-EPOCH regimen was administered according to 
original schedule with only one difference that pegylated 
filgrastim was administered instead of daily filgrastim on 
day 6 of regimen since it became available in Croatia. All 
patients had peripheral central line (PICC) inserted before 
the therapy.
Response evaluation was performed after four cycles of 
therapy. In case of complete remission (CR), patients re-
ceived additional two cycles. Otherwise, they received ad-
ditional four cycles, ie, a total of eight cycles, with the final 
evaluation performed after the treatment completion. All 
patients received six to eight cycles of rituximab concomi-
tantly. All patients received Pneumocystis jiroveci pneumo-
nia prophylaxis with trimethoprim-sulfamethoxazole twice 
a day, three times a week. Some patients also received anti-
viral and antifungal prophylaxis with acyclovir and flucon-
azole at physician’s discretion.
ASCT treatment
In patients undergoing ASCT, the last cycle of DA-EPOCH 
was used as a stem cell mobilization regimen. In these set-
tings, filgrastim administration was postponed after ANC 
nadir was reached, approximately 7-10 days after the last 
cycle of therapy. If unsuccessful, mini-BEAM (carmustine, 
etoposide, cytarabine, melphalan) chemotherapy or plerix-
afor were used before the stem cell apheresis. BEAM regi-
men was used for myeloablation.
Method
All patients that started one or more cycles of therapy 
or were planned to receive ASCT as a part of a first 
line therapy were included into analyses, thereby mimick-
ing intention to treat approach. Response to therapy was 
reported as overall response rate (ORR), complete remis-
sion (CR), partial remission (PR), progressive disease, and 
non-evaluable if treatment had to be discontinued before 
the disease evaluation could be performed due to reasons 
other than disease progression. Survival endpoints includ-
ing death for overall survival (OS) and death, progression, 
and relapse for progression free survival (PFS) were cal-
culated from the first day of therapy to the day of death, 
disease progression, relapse, or last follow-up as appropri-
ate. Patients who discontinued R-DA-EPOCH due to tox-
icity and continued treatment with alternative regimen 
were censored at the time of treatment discontinuation. 
Patients who discontinued R-DA-EPOCH due to disease 
progression or died during the treatment were marked as 
achieving an endpoint.
Statistical analysis
Normality of distribution of numerical variables was tested 
using the Kolmogorov-Smirnov test. Since most numerical 
variables were non-normally distributed, they are present-
ed as medians with interquartile range (IQR). Categorical 
variables were presented as proportions. Survival analy-
ses were performed using Kaplan-Meier method (28) and 
the log-rank test (29). The median follow-up was estimat-
ed using reverse Kaplan-Meier estimator (30). Data were 
screened using custom made MS Excel workbook (31) 
and reanalyzed using MedCalc Statistical Software version 
16.2.0 (MedCalc Software bvba, Ostend, Belgium). P < 0.05 
was considered statistically significant.
RESULTS
Clinical outcomes
The response to therapy was achieved in 60 of 75 treat-
ed patients (ORR 80%). Of 75 treated patients, 41 (55%) 
achieved CR, 19 (25%) achieved PR, and 5 (7%) had pro-
gressive disease. The response was non-evaluable in 10 of 
75 patients due to treatment discontinuation. When ana-
lyzed in evaluable patients only, response rates were 60/65 
(92%), 41/65 (63%), and 5/65 (29%) for ORR, CR, and PR, re-
spectively.
The 3-year and 5-year OS rates for all DLBCL patients were 
75% and 70%, respectively. The median follow-up time was 
29 months, and the median survival time was not reached 
(Figure 1). The 3-year and 5-year PFS rates for all DLBCL pa-
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tients were both 61%. The median follow-up time was 39 
months, and the median survival time was not reached (Fig-
ure 2). As expected, patients achieving CR had superior OS 
than patients achieving PR (HR 0.11; P = 0.001) or not achiev-
ing remission at all (HR 0.02; P < 0.001). Age (65-year cut-off ) 
had no prognostic impact on OS (Figure 3) or PFS (Figure 4). 
We did not observe any significant effect of other IPI-con-
tained risk factors (the Eastern Cooperative Oncology Group 
[ECOG] performance status ≥2, involvement of more than 
one extranodal site, increased lactate dehydrogenase [LDH], 
and advanced Ann Arbor stage [≥3]) on OS or PFS. Accord-
ingly, neither IPI nor R-IPI had a prognostic significance for 
OS or PFS in our cohort of patients. R-IPI-defined poor-risk 
group of patients showed very good survival rates: 4-year 
OS and PFS rates with 95% confidence intervals were 78% 
(64%-91%) and 61% (45%-77%), respectively.
Feasibility
The 75 patients included in the study received a total of 
455 cycles of therapy. The median number of administered 
cycles was six per patient (IQR 6-8). Dose adjustment was 
assessed in 71 patients with available data who received a 
total of 428 cycles. Doses were escalated in 134/428 (31%) 
cycles, lowered in 27/428 (6%) cycles, and unchanged in 
196/428 (46%) cycles, whereas 71/428 (17%) first cycles 
represent the difference to 100%.. The median number of 
cycles with dose escalation was two per patient (IQR 0-3) 
and reaching up to 249% of the initial dose in individual 
patients (dose escalated 4 times).
FIGURE 1. Overall survival (OS) in all 75 patients with diffuse 
large b-cell lymphoma. The 5-year and 3-year survival rates 
were 75% and 70%, respectively.
FIGURE 2. Progression free survival (PFS) in all 75 patients with 
diffuse large b-cell lymphoma. The 5-year and 3-year survival 
rates were both 61%.
FIGURE 3. Age impact on overall survival (OS) in all 75 patients 
with diffuse large b-cell lymphoma. There was no difference in 
OS between patients aged ≤65 years (full line) and >65 years 
(dashed line), P = 0.994.
FIGURE 4. Progression free survival (PFS) in all 75 patients 
with diffuse large b-cell lymphoma. There was no difference in 
PFS between patients aged ≤65 years (full line) and >65 years 
(dashed line), P = 0.827.
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Hematological and non-hematological toxicities
Hematological toxicity during the treatment was assessed 
in 63 patients with available data who received a total of 
371 cycles (Table 2). Hematologic toxicity grade 3 or 4 ac-
cording to National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (NCI CTCAE), version 4.0 
(32), was detected in all analyzed patients due to toxicity-
tailored nature of the regimen itself (dose adjustment ac-
cording to ANC). All patients with febrile neutropenia were 
hospitalized and treated accordingly. The median number 
of cycles with febrile neutropenia was one per patient (IQR 
0-2). The median cycle of febrile neutropenia occurrence 
was cycle four (IQR 2-5).
R-DA-EPOCH had to be discontinued in 9 of 75 patients 
due to inability to comply with regimen-related logistic re-
quirements (six-day hospitalization, frequent blood sam-
pling between cycles, PICC hygiene), treatment-related 
toxicity or unsatisfactory disease response to therapy. Nine 
of 75 patients died during the treatment. Three patients 
died due to disease progression and six died due to toxici-
ties including fatal sepsis originating in the respiratory tract 
(n = 2) or skin (n = 2; one catheter-related), fatal hepatitis B 
reactivation (n = 1), and thrombocytopenia-associated fa-
tal gastrointestinal hemorrhage (n = 1). We observed no 
significant doxorubicin-related cardiac toxicities. No sec-
ondary malignancies were detected.
ASCT subcohort
In the subset of 24 patients planed to receive ASCT, ORR 
was achieved in 21, CR in 15, and PR in 6 patients, whereas 
the response was not evaluable in 2 patients. The 3-year 
and 5-year OS rates were 80%. The median follow-up time 
was 43 months, whereas the median survival time was 
not reached (Figure 5). The 3-year and 5-year PFS rates in 
these 24 patients were both 79%. The median follow-up 
time was 43 months, and the median survival time was not 
reached (Figure 6).
Of 24 patients who were planned to receive ASCT, three 
died during the R-DA-EPOCH treatment (two due to infec-
tive complications and one due to disease progression). 
In 21 patients who completed R-DA-EPOCH, the last cycle 
TAbLE 2. Treatment-related hematological and non-hemato-
logical toxicities in patients with diffuse large b cell lymphoma
No. (%) 
of cycles
No. (%) 
of patients
Hematological toxicities*
anemia (grade 3 or 4)  65/371 (18.0) 36/63 (57.0)
thrombocytopenia (grade 3 or 4)  63/371 (17.0) 35/63 (56.0)
neutropenia (grade 4) 152/371 (41.0) 58/63 (92.0)
febrile neutropenia  66/371 (18.0) 40/63 (63.0)
Non-hematological toxicities
venous thrombosis   -  9/75 (12.0)
catheter-related   -  7/75 (9.0)
cerebrovascular infarction   -  1/75 (1.0)
polyneuropathy gr. ≥2   - 11/75 (15.0)
gastrointestinal hemorrhage   -  3/75 (4.0)
hepatitis B reactivation   -  1/75 (1.0)
hemorrhagic cystitis   -  1/75 (1.0)
Treatment discontinuation   -  9/75 (12.0)
Deaths during treatment   -  9/75 (12.0)
*Data available for 63 patients who received a total of 371 cycles.
FIGURE 5. Overall survival (OS) in 24 patients with diffuse large 
b-cell lymphoma planned to receive autologous stem cell 
transplantation (ASCT).
FIGURE 6. Progression free survival (PFS) in 24 patients with 
diffuse large b-cell lymphoma planned to receive autologous 
stem cell transplantation (ASCT).
45Pejša et al: R-DA-EPOCH and ASCT in patients with aggressive DLBCL
www.cmj.hr
of DA-EPOCH was used as a stem cell mobilizing regimen 
with 86% success rate (18 of 21 patients). The median time 
from the start of last cycle to the first stem cell apheresis 
was 17 days (IQR 16-18). Seventeen of 21 patients under-
went ASCT procedure, one patient withdrew the consent 
for the procedure, and three patients failed to collect ad-
equate graft. During ASCT, 13 of 17 patients developed fe-
brile neutropenia and one patient developed neutropen-
ic colitis requiring surgical intervention. The median time 
to ANC recovery was 11 days (IQR 10-11), and the median 
time to platelet count recovery was 12 days (IQR 12–14). 
There were no transplantation-related deaths, additional 
cardiac toxicities or secondary malignancies observed in 
this group of patients.
DISCUSSION
We found that R-DA-EPOCH followed by ASCT is an effec-
tive first-line treatment approach in DLBCL patients with 
unfavorable prognostic features. R-DA-EPOCH can surpass 
a negative prognostic impact of age on survival of patients. 
Our results also suggest that R-DA-EPOCH offers improved 
survival benefit in R-IPI defined “poor-risk” patients in com-
parison with previously reported 4-year OS rate of 55% in 
R-CHOP-treated patients (8).
DA-EPOCH was initially developed and used as the first-
line treatment for DLBCL patients at the US National Can-
cer Institute, with the reported 5-year OS and PFS rates of 
73% and 70%, respectively (20). In 2007, a Spanish group 
reported using R-DA-EPOCH for the treatment of poor 
prognosis DLBCL patients and achieving 2-year OS and 
event-free survival (EFS) rates of 75% and 68%, respec-
tively, with aaIPI≥3 as the only factor related to poor EFS 
(21). Recently, another group from Spain reported 10-year 
OS and EFS rates of 64% and 48%, respectively, in R-DA-
EPOCH-treated patients with poor prognosis DLBCL (33). 
ASCT has been extensively discussed as part of first-line 
therapy for aggressive non-Hodgkin lymphomas, especial-
ly DLBCL (26,34-36), where consolidation using high-dose 
therapy and ASCT was shown to reduce relapse rate, main-
ly in a subgroup of high-risk patients (37-39). In 2008, Greb 
et al (25) reported a Cochrane database review including 
more than 3000 patients and concluded that initial CR rate 
superiority did not translate into OS, ie, OS and EFS were 
the same regardless of whether the patients were treated 
with conventional chemotherapy or high-dose therapy 
followed by ASCT. This lack of survival benefit was reason 
not to include or recommend ASCT as a standard part of 
first-line therapy. Additional data from the results of the 
SWOG Intergroup phase III trial demonstrated that the ad-
dition of ASCT resulted in a significantly higher 2-year PFS 
but no difference in 2-year OS was observed. Subset analy-
ses showed that the benefit of ASCT was found primarily in 
patients with high-IPI disease, in whom 2-year OS rate was 
82% (ASCT) vs 64% (27). Our results regarding the 5-year 
OS and PFS in our DLBCL patients and those planned to 
receive ASCT are in line with previous experiences with R-
DA-EPOCH regimen in similar cohorts of patients. As sug-
gested by PFS survival curves, our patients achieving re-
mission and not progressing over 2 years of follow-up are 
probably cured.
Our study sample included some patients with IPI<2 but 
with a very high proliferation index (and otherwise unfa-
vorable disease features), which is partly the reason why IPI 
and R-IPI showed no prognostic significance. Also, dynam-
ic dose adjustment tailored to the hematopoietic reserve 
of individual patients allowed for the application of the 
highest acceptable doses and maximization of therapeu-
tic effect. This approach inevitably results in an increased 
hematologic toxicity, but it enables optimal treatment of 
elderly patients and abrogates negative prognostic signifi-
cance of age on survival (included into IPI and R-IPI scores). 
Increased hematologic toxicity, treatment discontinuation, 
and deaths during treatment do not offset high survival 
rates in our cohort of patients. Further benefit observed 
was the ability to use the last cycle of DA-EPOCH therapy 
for stem cell mobilization with 86% success rate, reducing 
the need for additional stem cell mobilizing regimen and 
associated risks.
Experience with combination of DA-EPOCH with ASCT as 
part of first-line therapy for poor-risk non-Hodgkin lym-
phomas is still lacking despite the promising results with 
double-hit lymphomas (40). Although we were unable to 
discriminate patients with double-hit lymphomas, our in-
clusion criteria based on very high proliferation rates and 
unfavorable prognostic features probably pooled such pa-
tients. Results of immunochemotherapy regimens in dou-
ble-hit lymphomas are unsatisfactory. Petrich et al (40) re-
ported median PFS and OS rates for the entire cohort of 
10.9 and 21.9 months, respectively, and the PFS and OS 
rates at 2 years of 40% and 49%, respectively. In the first 
meta-analysis of patients with double-hit lymphomas, 
Howlett et al (23) found that median PFS for the R-CHOP, 
R-EPOCH, and other intensive regimens groups was 12.1, 
22.2, and 18.9 months, respectively. First-line treatment 
with R-EPOCH significantly reduced the relative risk of 
a progression compared with R-CHOP by 34%; how-
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ever, OS was not significantly different across treatment 
approaches. They also presumed that a subset of patients 
might benefit from intensive induction with or without 
transplant (23). These results showed that R-DA-EPOCH is 
the only regimen that provides PFS advantage, but with-
out OS benefit. Most patients with double-hit lymphomas 
are within the group of DLBCL patients with high Ki-67%. 
Their treatment results are significantly worse than in other 
DLBCL patients and those in our cohort. Thus, we assume 
that patients with double-hit lymphomas comprised only 
a minority among our patients.
In search for better treatment options for high-risk DL-
BCL patients, many intensive regimens were evaluated 
with mostly dose densing or intensification and etopo-
side addition. Schmitz et al (15) reported the 3-year EFS of 
69.5% and 61.4% in the R-CHOEP14- and R-MegaCHOEP-
treated patients, respectively, without a statistical signifi-
cance. Doubling and densing rituximab therapy in addi-
tion to CHOEP14 did not improve results (41). However, 
these were all young patients with high-risk disease. The 
results of R-CHOP treatment in older patients are not so 
favorable. In the International Society of Geriatric Oncol-
ogy (SIOG) expert position commentary by Morrison et al 
(42), CR rates were 50% in patients aged 65–75 years, and 
40% in those aged >75 years. Median remission duration 
was 16 months; cure rates were 50%–60% in younger and 
25%–30% in older patients.
Our study had a few limitations, including retrospective de-
sign, single-center experience, and inability to discriminate 
double-hit lymphomas from other DLBCL subsets. High lo-
gistic requirements of R-DA-EPOCH regimen resulted in 
lower threshold for treatment discontinuation in some pa-
tients experiencing otherwise manageable complications. 
The effects of treatment discontinuation on outcome mea-
sures were taken into account by analyzing the treatment 
response in both the complete cohort and evaluable pa-
tients only, and by using strict inclusion and censoring cri-
teria regarding the patients who progressed or died during 
treatment (we included all patients who had received ≥1 
cycle of therapy). The strengths of our study are mimick-
ing the intention-to-treat approach, respectable number 
of patients treated, and long follow-up.
In conclusion, our results in one of the largest cohorts of 
patients outside the US National Cancer Institute showed 
that R-DA-EPOCH is a very effective therapeutic option 
as the first-line treatment for DLBCL patients with unfa-
vorable prognostic features irrespective of their age. 
ASCT provides additional benefit for a selected group of 
patients with acceptable toxicity.
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